ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$1.55
0.07 (4.73%)
β²
5d:
+28.1%
30d:
+22.05%
90d:
+42.2%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR BETTER ENTRY: ENTX is 16.5% above its trading range ($1.33). While momentum could continue, risk/reward favors waiting for a pullback.
βΈοΈ WAIT FOR BETTER ENTRY: ENTX is 16.5% above its trading range ($1.33). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $1.55, which is considered extended relative to its 30-day fair value range of $1.16 to $1.33.
Technical Outlook: Technically, ENTX is in a downtrend. The price is approaching resistance at $1.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ENTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+480.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENTX is in a downtrend. The price is approaching resistance at $1.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: ENTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+480.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.16 -
$1.33
Company Quality Score
56/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+16.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 480.6% below Wall St target ($9.00)
- WARNING: Recommendation downgraded due to 16.5% overvaluation
Trading Range Analysis
30-Day Trading Range
$1.16 -
$1.33
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$1.37
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.72
Wall Street Target
$9.00
(+480.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 24, 2026 8:01 AM ET
Data refreshes hourly during market hours. Next update: 9:01 AM
Data refreshes hourly during market hours. Next update: 9:01 AM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Geno J Germano
BUY
20000 shares
2026-03-09
Sean Ellis
BUY
10000 shares
2026-03-05
Sean Ellis
BUY
18000 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I⦠|
STRONG BUY
14 analysts |
$105 | 57 HOLD |